During the past 20 years, hundreds of thousands of women with breast cancer have taken the drug Herceptin, typically for a year or more. The medicine, used to treat an aggressive form of the disease, ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive long-term follow-up data from the pivotal, Phase III ...
High TILs may predict which patients with early HER2-positive breast cancer may have a reduced risk for disease relapse or death with Herceptin treatment. High tumor infiltrating lymphocytes (TILs) in ...
Cleveland Clinic researchers have found that nearly two-thirds of patients with HER2-positive metastatic breast cancer did ...
– At three years, 88.3 percent of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared to 77.0 percent treated with ...
Please provide your email address to receive an email when new articles are posted on . Researchers observed a DFS benefit with 1 year of trastuzumab compared with 9-week administration. OS rates at 5 ...
Dennis Slamon ONCOLOGY Professor of Medicine; Chief, Division of Hematology/Oncology; Associate Director of ...
Shanghai Henlius Biotech’s partner, Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, has received permission from the Food and Drug Administration for Hercessi (HLX02, ...
ZURICH (Reuters) - Roche Holding AG's Herceptin combined with Pertuzumab showed "impressive results" in a Phase II breast cancer trial, the Swiss drugmaker said on Friday. For the Roche statement, ...
A recent study provided new evidence about the effect that the entry of biosimilars has on lowering the price of cancer treatments covered by Medicare. The study, published in the Journal of Clinical ...
Using human tumors in nude mice, the so-called xenograft experiment, showed a significant suppression of the human tumor (Figure 12). The growth of human tumor was delayed and suppressed by homophilic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results